文献速递血栓与止血

遗传性出血性疾病患者接受凝血因子浓缩物或双特异性抗体治疗后的血栓发生率:EUHASS 十五年数据

Thrombotic rates in individuals with inherited bleeding disorders treated with concentrate or bispecific antibody. Fifteen-year EUHASS data.
PubMed 文献 · J Thromb Haemost · 2026-10-03

基于 EUHASS 监测系统 2008 年 10 月至 2023 年 12 月、27 国 95 个哨点中心的数据,分析遗传性出血性疾病患者接受凝血因子浓缩物或 emicizumab 治疗后 30 天内血栓事件。15 年间 209,842 治疗年中发生 204 例血栓,血友病 A 和 B 接受对应因子浓缩物治疗的血栓率低于每 1000 患者年 1.0 次。

要点

  • 血友病 A 和 B 接受 FVIII 和 IX 浓缩物治疗的血栓率低于每 1000 患者年 1.0 次。
  • emicizumab 血栓率为每 1000 患者年 0.92 次。
  • 纤维蛋白原浓缩物治疗者血栓率最高,为每 1000 患者年 11.56 次。

核心结论

  • 血友病 A 和 B 患者分别接受 FVIII 和 IX 浓缩物治疗后的血栓率低于每 1000 患者年 1.0 次,该信息可用于与新型产品的血栓率进行比较。

研究设计与样本

  • 分析 EUHASS 系统报告的血栓事件,EUHASS 为欧洲遗传性出血性疾病患者接受凝血因子浓缩物和/或 emicizumab 治疗的不良事件监测系统。
  • 95 个哨点中心来自 27 个国家参与,报告 2008 年 10 月至 2023 年 12 月期间产品给药后 30 天内发生的血栓事件及每种产品治疗人数。
  • 共 209,842 治疗年,发生 204 例血栓事件,其中血友病 A 113 例、血友病 B 22 例、血管性血友病 22 例、其他出血性疾病 47 例。

主要发现

  • 血浆源性 FVIII 血栓率为每 1000 患者年 1.10 次。
  • 重组标准半衰期 FVIII 血栓率为每 1000 患者年 0.70 次,延长半衰期 FVIII 为每 1000 患者年 0.52 次。
  • emicizumab(Hemlibra)血栓率为每 1000 患者年 0.92 次。
  • 纤维蛋白原浓缩物治疗者血栓率最高,为每 1000 患者年 11.56 次。

临床怎么用

  • 血友病 A 和 B 患者接受 FVIII 和 IX 浓缩物治疗时血栓风险较低,可低于每 1000 患者年 1.0 次。
  • 纤维蛋白原浓缩物治疗者血栓率最高,为每 1000 患者年 11.56 次,临床需关注。
  • emicizumab 血栓率为每 1000 患者年 0.92 次,可与新引入产品比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although inherited bleeding disorders are associated with a reduced risk of thrombosis, the rate of thrombosis following treatment of the bleeding disorders is unknown. OBJECTIVE: To determine the rates of thrombosis in persons with inherited bleeding disorders treated with clotting factor concentrates or a bispecific antibody. METHODS: Analysis of the thrombotic events reported to the EUHASS system. EUHASS is the European surveillance system for adverse events in persons with all inherited bleeding disorders treated with clotting factor concentrates and/or emicizumab. 95 sentinel centres from 27 countries participated. From 10/2008 to 12/2023, thrombotic events occurring within 30 days of product administration, and the number of persons treated with each product were reported. Annual thrombosis rates (95% confidence intervals-CI) according to the product were compared using rate ratios. RESULTS: During the 15-year period, 204 episodes of thrombosis occurred in 209,842 treatment years 113 events were in hemophilia A, 22 in hemophilia B, 22 in von Willebrand disease, and 47 in other bleeding disorders. The rates of thrombosis following plasma-derived FVIII was 1.10, recombinant standard half-life FVIII 0.70 and extended half-life FVIII 0.52 per 1000 patient years. The rate for emicizumab (Hemlibra) was 0.92 per 1000 patient years. The highest rate was in persons treated with fibrinogen concentrate at 11.56 per 1000 patient years. CONCLUSION: The rate of thrombosis in persons with hemophilia A and B treated with FVIII and IX concentrates, respectively, is less than 1.0 per 1000 patient years. This information can be used in comparisons with rates for newly introduced products.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Makris M, Fischer K, Gatt A, et al. Thrombotic rates in individuals with inherited bleeding disorders treated with concentrate or bispecific antibody. Fifteen-year EUHASS data. J Thromb Haemost. 2026. PMID: 42829087. doi:10.1016/j.jtha.2026.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。